+7 (499) 340 10 14

Effective in Behavior Disorders.

A new drug for treatment of psychotic disorders  will soon be available in the Russian market.

It refers to periciazin, its development was performed within the framework of the Federal Target Program Russian Pharmaceutical and Healthcare Industry of the Russian Federation until 2020 and Further”.

The drug is a piperidine derivative of phenotiazine group agent and is intended for treatment of psychotic disorders. It has mild antipsychotic and sedative effects without a stimulating component, it has adrenolytic, spasmolytic, parasympatolytic, antiemetic, hypothermic effects, decreases irritability and aggression, that is why it is called a behavior corrector in healthcare setting.

An open randomized crossover two-stage comparative bioequivalence study of periciazine in capsules (JSC R-Pharm, Russia) and a similar drug with healthy volunteers. Comparison of pharmacokinetic parameters of generic and reference drugs supported its bioequivalence.

Drug manufacturer State Company R-Pharm obtained a marketing authorization certificate LP-003560 of 12.04.2016 RF MoH.

Periciazine is included into the list of Vital and Essential  drugs for medicinal use in the Russian Federation (2016). Its manufacture will be organized at the Yaroslavl plant of finished pharmaceutical forms R-Pharm, that fully meets Russian and international manufacturing practice standards.

LABMGMU LABMGMU +7 (499) 340 10 14 info@labmgmu.ru 119435, Moscow, Malaya Pirogovskay str. 13-1, floor 4